Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial
Sherman KE, Sjogren M, Creager RL, et al. Hepatology 1998;27:1128-1135.
What it found
End-of-treatment normalisation of liver enzymes occurred in 37.1% on the combination, 16.2% on interferon alone and 2.7% on placebo; viral clearance was 37.1% versus 18.9%. Sustained responses after stopping were 14.2% and 8.1%.
Limitations
Interferon-era trial; hepatitis C is now managed with direct-acting antivirals, so the results have little current relevance. Sustained responses were low.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.